Acute Rhinosinusitis (Adult)

Overview

Acute rhinosinusitis (ARS) is a symptomatic inflammation of the nasal cavity and paranasal sinuses lasting less than 4 weeks. [1] The condition represents one of the most common reasons for antibiotic prescription in primary care, with an estimated 31 million cases annually in the United States. [2] However, the vast majority (90-98%) of acute rhinosinusitis is viral in origin and self-limiting, resolving spontaneously within 7-10 days without antibiotic therapy. [3,4]

Acute bacterial rhinosinusitis (ABRS) develops in only 0.5-2% of viral upper respiratory tract infections when bacterial superinfection occurs. [1,5] Distinguishing viral from bacterial disease is critical for appropriate antibiotic stewardship, as unnecessary antibiotic use contributes to antimicrobial resistance and exposes patients to potential adverse effects without clinical benefit. [6]

The paranasal sinuses include the maxillary, ethmoid, frontal, and sphenoid sinuses, all of which drain into the nasal cavity through the ostiomeatal complex. Obstruction of sinus drainage and ventilation, typically secondary to viral infection-induced mucosal inflammation, creates the conditions for bacterial overgrowth and purulent infection. [7] While most cases are managed conservatively with symptomatic treatment, recognition of complications involving orbital or intracranial extension is essential, as these represent life-threatening emergencies requiring urgent imaging, intravenous antibiotics, and surgical consultation. [8,9]

---

Epidemiology

Prevalence and Incidence

Acute rhinosinusitis affects 6-15% of the population annually, making it one of the most frequent diagnoses in ambulatory care. [2,10] In the United States alone, sinusitis accounts for approximately 31 million cases per year, generating 16 million outpatient visits and costs exceeding $3.5 billion in direct healthcare expenditures. [2]

Demographics

Acute rhinosinusitis affects all age groups but shows peak incidence in young and middle-aged adults. [10] The condition is more common during winter months, coinciding with increased viral upper respiratory tract infection transmission. [11] No significant sex predilection exists for uncomplicated acute rhinosinusitis, though chronic rhinosinusitis demonstrates slight male predominance. [12]

Risk Factors

Several factors predispose to development of acute rhinosinusitis:

Anatomic factors:

• Septal deviation or nasal valve collapse
• Concha bullosa or paradoxical middle turbinate
• Adenoid hypertrophy (pediatric patients)
• Previous facial trauma or surgery

Mucosal factors:

• Allergic rhinitis (present in 25-30% of ARS patients) [13]
• Non-allergic rhinitis
• Ciliary dyskinesia (primary or acquired)
• Cystic fibrosis

Environmental factors:

• Cigarette smoking (active or passive)
• Air pollution exposure
• Swimming and diving (barotrauma)
• Airplane travel with barotrauma

Immunologic factors:

• HIV/AIDS
• Common variable immunodeficiency
• IgG subclass deficiency
• Diabetes mellitus
• Corticosteroid therapy

Iatrogenic factors:

• Nasogastric or nasotracheal intubation
• Nasal packing
• Dental procedures involving maxillary teeth

---

Aetiology and Pathophysiology

Microbiological Aetiology

Viral Pathogens

Viral rhinosinusitis accounts for 90-98% of all acute rhinosinusitis cases. [3,4] The most commonly implicated viral pathogens include:

Viral infection triggers an inflammatory cascade involving cytokine release (IL-1, IL-6, IL-8, TNF-α), increased vascular permeability, mucosal edema, and hypersecretion of mucus. [7] Ciliary function becomes impaired, reducing mucociliary clearance and creating conditions favourable for bacterial colonisation. [14]

Bacterial Pathogens

When bacterial superinfection develops (0.5-2% of viral URIs), [1,5] the following organisms predominate:

Pneumococcal resistance to penicillin has increased in many regions, with 15-30% showing intermediate or high-level resistance. [15] However, amoxicillin at standard or high doses remains effective for most strains due to achievable tissue concentrations. [16] Resistance of H. influenzae and M. catarrhalis to amoxicillin via β-lactamase production (30-50% and > 90%, respectively) necessitates use of β-lactamase inhibitor combinations as first-line therapy. [1]

Fungal Pathogens

Fungal rhinosinusitis is uncommon in immunocompetent hosts but represents a medical emergency in immunocompromised patients:

• Allergic fungal rhinosinusitis (AFRS): Hypersensitivity reaction to fungal antigens (Aspergillus, dematiaceous fungi), seen in atopic individuals
• Acute invasive fungal sinusitis: Life-threatening infection in immunocompromised hosts (neutropenia, diabetes with ketoacidosis, transplant recipients), typically Mucor, Rhizopus, Aspergillus species [17]
• Chronic invasive fungal sinusitis: Slowly progressive disease over months to years in mildly immunocompromised hosts
• Fungal ball (mycetoma): Non-invasive colonisation, typically maxillary sinus

Pathophysiology

The pathophysiology of acute rhinosinusitis follows a characteristic sequence:

1. Initial Viral Infection

Viral pathogens bind to respiratory epithelium via specific receptors (e.g., ICAM-1 for rhinovirus, sialic acid residues for influenza). [7] Viral replication triggers:

• Release of pro-inflammatory cytokines (IL-1β, IL-6, IL-8, TNF-α)
• Increased vascular permeability and plasma extravasation
• Mucosal edema and hyperemia
• Stimulation of mucus-secreting goblet cells
• Downregulation of ciliary beat frequency

2. Ostiomeatal Complex Obstruction

The ostiomeatal complex (OMC) represents the narrow common drainage pathway for the maxillary, frontal, and anterior ethmoid sinuses. [7] Mucosal edema at this critical anatomical region obstructs sinus ostia, preventing:

• Normal sinus ventilation (creating negative pressure)
• Mucociliary clearance of secretions
• Oxygen tension maintenance (creating hypoxic environment)

3. Mucus Stasis and Bacterial Overgrowth

Retained mucus within obstructed sinuses provides an ideal culture medium for bacterial proliferation. Normally, nasal colonising bacteria (S. pneumoniae, H. influenzae, M. catarrhalis) are kept at low levels by mucociliary clearance and innate immune mechanisms. [14] Stasis allows exponential bacterial growth from colonisation (10³-10⁴ CFU/mL) to infection levels (10⁵-10⁷ CFU/mL).

The hypoxic, acidic environment within obstructed sinuses favours facultative anaerobes. Bacterial biofilm formation on sinus mucosa contributes to persistence and recurrent infection by protecting bacteria from host immune responses and antibiotics. [18]

4. Purulent Inflammation

Bacterial infection triggers neutrophil recruitment, phagocytosis, and release of proteolytic enzymes and reactive oxygen species. This creates purulent exudate rich in dead neutrophils, bacterial debris, and inflammatory mediators. Mucosal inflammation becomes self-perpetuating through continued cytokine production and tissue injury.

5. Potential Complications

In rare cases (less than 2%), infection extends beyond the confines of the paranasal sinuses: [8,9]

• Orbital complications: Infection breaches the thin lamina papyracea (medial orbital wall), causing preseptal cellulitis, orbital cellulitis, subperiosteal abscess, or orbital abscess
• Intracranial complications: Infection spreads via venous channels (valveless facial and ophthalmic veins) or direct bony erosion, causing meningitis, epidural abscess, subdural empyema, brain abscess, or cavernous sinus thrombosis
• Osteomyelitis: Frontal bone involvement (Pott's puffy tumour)

Exam Detail: Molecular Mechanisms of Bacterial Adhesion and Biofilm Formation:

Streptococcus pneumoniae utilises multiple surface adhesins for epithelial binding:

• Pneumococcal surface protein A (PspA): Inhibits complement deposition
• Choline-binding protein A (CbpA): Binds polymeric immunoglobulin receptor
• Pneumococcal adhesion and virulence factor A (PavA): Binds fibronectin

Following adhesion, bacteria form biofilms via quorum sensing mechanisms. Biofilms consist of bacterial microcolonies embedded in self-produced extracellular polymeric substance (EPS) matrix composed of polysaccharides, proteins, and extracellular DNA. [18] This matrix:

• Impairs antibiotic penetration (up to 1000-fold increased resistance)
• Protects against neutrophil phagocytosis
• Creates nutrient gradients favouring persister cell formation
• Enables horizontal gene transfer of resistance determinants

Biofilm bacteria exhibit markedly different gene expression compared to planktonic forms, with upregulation of stress response genes and downregulation of growth-related genes, contributing to antibiotic tolerance and chronic infection.

Ciliary Dysfunction in Rhinosinusitis:

Normal ciliary beat frequency (CBF) is 12-15 Hz at 37°C. Viral infection and inflammatory mediators reduce CBF through:

• Direct viral cytopathic effects on ciliated epithelium
• Inflammatory mediators (IL-1β, TNF-α, neutrophil elastase) disrupting ciliary axoneme structure
• Altered calcium signaling affecting dynein arm function
• Oxidative stress damaging ciliary microtubules

Recovery of normal ciliary function may take 2-6 weeks post-viral infection, explaining the prolonged course of post-viral rhinosinusitis symptoms even after viral clearance.

---

Clinical Presentation

Symptoms

The diagnosis of acute rhinosinusitis requires the presence of two or more cardinal symptoms, one of which must be nasal obstruction/congestion or nasal discharge: [1,19]

Cardinal Symptoms (Diagnostic Criteria)

1. Nasal obstruction/congestion (96% of patients)

   • Bilateral or unilateral
   • Worse when recumbent
   • Relieved temporarily by decongestants

2. Nasal discharge (89% of patients)

   • Anterior rhinorrhea: visible at nostrils
   • Posterior rhinorrhea: postnasal drip sensation
   • Character: Clear (viral) → mucopurulent → purulent (bacterial)
   • Color alone does not distinguish viral from bacterial

3. Facial pain/pressure (83% of patients)

   • Localized to affected sinus distribution
   • Maxillary: cheek, upper teeth, infraorbital region
   • Frontal: forehead, supraorbital region
   • Ethmoid: between/behind eyes, nasal bridge
   • Sphenoid: vertex, occiput, retro-orbital (rare in acute)
   • Worse with bending forward, Valsalva, coughing

4. Reduction/loss of smell (hyposmia/anosmia) (68% of patients)

   • Due to olfactory cleft edema blocking odorant access
   • Conductive rather than sensorineural mechanism
   • Improvement parallels symptom resolution

Associated Symptoms

• Headache: Dull, constant pain; not diagnostic but common
• Cough: Predominantly from postnasal drip; worse at night
• Ear fullness/pressure: Due to Eustachian tube dysfunction
• Halitosis: From anaerobic bacterial metabolism
• Dental pain: Maxillary sinusitis causes referred pain to upper molars/premolars
• Fatigue/malaise: Systemic inflammatory response
• Fever: Variable; more common in bacterial infection but not specific

Differentiating Viral from Bacterial Rhinosinusitis

This distinction is critical for antibiotic stewardship. The IDSA and AAO-HNS guidelines provide three clinical criteria for bacterial rhinosinusitis: [1,19]

IDSA/AAO-HNS Criteria for Acute Bacterial Rhinosinusitis

Diagnosis of ABRS requires one or more of the following:

1. Persistent symptoms ≥10 days without improvement

   • Most viral rhinosinusitis resolves by day 7-10
   • Symptoms neither worsening nor improving
   • Most specific criterion (positive predictive value 60-70%)

2. Severe symptoms at onset (≥3 consecutive days)

   • Fever ≥39°C (102.2°F) AND
   • Purulent nasal discharge AND
   • Facial pain/pressure
   • Less common presentation (less than 5-10% of bacterial cases)

3. Worsening symptoms after initial improvement ("double-sickening")

   • Symptoms initially improve (suggesting viral URI resolution)
   • New onset fever, nasal discharge, or facial pain after day 5-6
   • Positive predictive value ~80% for bacterial infection

Features That Do NOT Distinguish Viral from Bacterial

• Purulent (colored) discharge: Occurs in both viral and bacterial infection due to neutrophil recruitment; color alone has poor specificity [20]
• Unilateral symptoms: Can occur in viral infection
• Maxillary toothache: Common in viral maxillary sinusitis
• Poor response to decongestants: Not predictive

Physical Examination

Physical examination is often unrevealing but should include:

General Appearance

• Assess for toxic appearance (suggests complications)
• Respiratory distress (suggests extensive disease)

Nasal Examination

Anterior rhinoscopy (with otoscope or nasal speculum):

• Mucosal erythema and edema
• Purulent discharge in nasal cavity or middle meatus
• Nasal polyps (suggests chronic disease)
• Septal deviation
• Turbinate hypertrophy

Nasal endoscopy (if available, not routine):

• Direct visualization of middle meatus and ostiomeatal complex
• Identification of purulent drainage from sinus ostia
• Assessment of anatomical variants
• Not required for diagnosis in uncomplicated cases

Facial Examination

• Percussion tenderness over sinuses:

  • "Maxillary: tapping over cheeks"
  • "Frontal: tapping over forehead"
  • Sensitivity 40-50%, specificity 60-70% (limited diagnostic utility)

• Palpation tenderness: Direct pressure over sinuses

• Transillumination: Darkening of sinuses with light

  • Poor sensitivity and specificity; not recommended [19]

Oropharyngeal Examination

• Postnasal drip visualization
• Pharyngeal erythema (associated viral pharyngitis)
• Dental examination for odontogenic source

Red Flag Examination Findings

Orbital involvement:

• Periorbital edema or erythema
• Proptosis
• Ophthalmoplegia (limited extraocular movements)
• Diplopia
• Decreased visual acuity
• Relative afferent pupillary defect (RAPD)

Intracranial involvement:

• Altered mental status
• Severe headache out of proportion to rhinosinusitis
• Meningismus (neck stiffness, photophobia)
• Focal neurological deficits
• Seizures

Severe local infection:

• Facial cellulitis
• Frontal swelling (Pott's puffy tumour)
• Cranial nerve palsies

---

Red Flags and Complications

Complications of acute rhinosinusitis, though rare (less than 2%), are potentially life-threatening and require immediate recognition and management. [8,9]

Orbital Complications

The orbit is the most common site of rhinosinusitis complications, particularly from ethmoid sinusitis, due to the thin lamina papyracea separating the sinuses from the orbit. [8] The Chandler classification stratifies orbital complications:

Warning signs requiring urgent ophthalmology/ENT consultation:

• Any proptosis
• Diplopia or ophthalmoplegia
• Decreased visual acuity
• Relative afferent pupillary defect (RAPD)
• Worsening despite 24-48 hours IV antibiotics

Intracranial Complications

Intracranial spread occurs via:

• Direct extension: Bony erosion through posterior frontal sinus wall or cribriform plate
• Thrombophlebitis: Retrograde spread through valveless diploic and emissary veins

Warning signs requiring urgent neurosurgical consultation:

• Severe headache disproportionate to rhinosinusitis
• Altered mental status or confusion
• Focal neurological deficits
• Seizures
• Papilledema
• Signs of raised intracranial pressure

Osseous Complications

Pott's puffy tumour: Frontal bone osteomyelitis with subperiosteal abscess, presenting as forehead swelling with doughy consistency. [9] Requires IV antibiotics and surgical debridement.

When to Image and Refer

---

Differential Diagnosis

Other Causes of Nasal/Facial Symptoms

Red Flags Suggesting Alternative Diagnosis

• Unilateral symptoms with epistaxis: Neoplasm, granulomatosis with polyangiitis
• Cranial nerve palsies: Neoplasm, invasive fungal sinusitis, skull base osteomyelitis
• Severe symptoms in immunocompromised host: Invasive fungal sinusitis
• Black nasal discharge or eschar: Invasive fungal sinusitis (mucormycosis)
• Proptosis without infection signs: Orbital tumor, thyroid eye disease

---

Diagnostic Approach

Clinical Diagnosis

Acute rhinosinusitis is a clinical diagnosis based on history and physical examination. [1,19] No laboratory or imaging studies are required for uncomplicated cases.

Diagnostic criteria (EPOS 2020): [19]

• Sudden onset of ≥2 symptoms, one of which must be nasal blockage/congestion or nasal discharge (anterior/posterior drip):
  • ± Facial pain/pressure
  • ± Reduction/loss of smell
• Duration less than 12 weeks
• Complete symptom resolution between episodes (if recurrent)

Imaging

When NOT to Image

Imaging is not indicated for: [1,19]

• Uncomplicated acute rhinosinusitis (viral or bacterial)
• Symptoms less than 4 weeks duration without red flags
• Response to appropriate therapy

Routine imaging leads to:

• Overdiagnosis (abnormal findings in asymptomatic individuals)
• Increased cost without improved outcomes
• Radiation exposure
• Incidental findings requiring further investigation

When to Image

Indications for CT sinuses (with IV contrast if complications suspected):

1. Suspected complications (orbital, intracranial, osseous)
2. Recurrent acute rhinosinusitis (≥4 episodes/year) to evaluate for:
   • Anatomical abnormalities (septal deviation, concha bullosa)
   • Chronic mucosal disease
   • Nasal polyps
3. Failed medical therapy (symptoms persist after 2 courses of antibiotics)
4. Pre-operative planning for functional endoscopic sinus surgery (FESS)
5. Immunocompromised patients with sinusitis (lower threshold for imaging)
6. Suspected fungal sinusitis
7. Nosocomial sinusitis in ICU patients

CT findings in acute rhinosinusitis:

• Air-fluid levels (highly specific for bacterial infection)
• Complete sinus opacification
• Mucosal thickening > 4-5mm
• Ostiomeatal complex obstruction

Note: Mucosal thickening is common in asymptomatic individuals, especially during/after viral URIs. Imaging findings must be interpreted in clinical context.

MRI indications:

• Suspected intracranial complications (better soft tissue detail)
• Suspected fungal sinusitis (better for assessing orbital/intracranial extension)
• Tumor evaluation
• Not first-line for uncomplicated sinusitis

Laboratory Investigations

Laboratory tests are not routinely indicated for uncomplicated acute rhinosinusitis.

Consider in specific scenarios:

Sinus aspiration: Gold standard for microbiologic diagnosis but invasive, reserved for:

• Severe complications
• Immunocompromised patients
• Nosocomial sinusitis
• Failed therapy with multiple antibiotics

---

Classification

By Duration

By Aetiology

By Sinus Involvement

• Maxillary sinusitis: Most common (70-80%)
• Ethmoid sinusitis: Common (60-70%), especially children
• Frontal sinusitis: 10-20%
• Sphenoid sinusitis: Rare (5%), often missed
• Pansinusitis: Involvement of all sinuses

---

Management

The management of acute rhinosinusitis focuses on:

1. Distinguishing viral from bacterial infection
2. Symptomatic treatment for viral disease
3. Judicious antibiotic use for bacterial disease
4. Recognition and management of complications

General Principles

Antibiotic stewardship: [6]

• 81% of patients diagnosed with rhinosinusitis receive antibiotics
• Only 0.5-2% have bacterial infection requiring antibiotics
• Overuse drives antimicrobial resistance and adverse effects
• Number needed to treat (NNT) for antibiotics in unselected rhinosinusitis patients: 15-18 for symptom improvement [3]

Watchful waiting: [1]

• For patients meeting criteria for ABRS but with mild symptoms
• Offer symptomatic treatment and delayed antibiotic prescription
• Instruct to fill prescription if no improvement in 7 days or worsening at any time
• Reduces antibiotic use by 30-40% without compromising outcomes

Viral Rhinosinusitis (Symptomatic Management)

For the 90-98% of patients with viral disease: [3,4]

Saline Nasal Irrigation

Most effective symptomatic treatment with Level I evidence. [21]

• Mechanism: Mechanical clearance of mucus, reduction of inflammatory mediators, improved mucociliary function
• Regimen: Isotonic or hypertonic saline, 150-250mL per nostril, 2-3 times daily
• Devices: Neti pot, squeeze bottle, nasal irrigation system
• Safety: Use sterile, distilled, or previously boiled water (risk of Naegleria fowleri with tap water)
• Evidence: Cochrane review shows improved symptoms and reduced antibiotic use [21]

Intranasal Corticosteroids

Modest benefit for symptom relief. [22]

• Agents: Fluticasone propionate, mometasone furoate, budesonide
• Dose: 1-2 sprays per nostril once or twice daily
• Mechanism: Reduce mucosal inflammation and edema
• Evidence: Meta-analyses show small but significant symptom improvement versus placebo (NNT ~15)
• Onset: 12-24 hours; maximal effect at 3-7 days
• Role: Adjunctive therapy; consider for patients with allergic rhinitis component

Oral Analgesics

• Paracetamol: 500-1000mg every 4-6 hours (max 4g/24h)
• Ibuprofen: 400-600mg every 6-8 hours (max 2.4g/24h)
• Evidence: Effective for facial pain/headache; no effect on congestion

Decongestants

Topical α-agonists (use limited to ≤3 days):

• Agents: Oxymetazoline 0.05%, xylometazoline 0.1%
• Dose: 2-3 sprays per nostril twice daily
• Mechanism: Vasoconstriction reduces mucosal edema
• Warning: Rebound congestion (rhinitis medicamentosa) if used > 3 days
• Role: Short-term relief for severe obstruction

Oral decongestants:

• Agent: Pseudoephedrine 60mg every 4-6 hours (max 240mg/24h)
• Mechanism: Systemic α-agonist causes nasal vasoconstriction
• Contraindications: Uncontrolled hypertension, coronary artery disease, hyperthyroidism, concurrent MAO inhibitor use
• Evidence: Modest improvement in nasal obstruction [23]
• Side effects: Insomnia, nervousness, palpitations, urinary retention (men with BPH)

Antihistamines

• Role: NOT recommended for non-allergic rhinosinusitis [1,19]
• Mechanism: Block H1 receptors; reduce allergic inflammation
• Evidence: No benefit in viral rhinosinusitis; may worsen symptoms by thickening secretions
• Exception: May use if concurrent allergic rhinitis

Mucolytics

• Agents: Guaifenesin, N-acetylcysteine
• Evidence: Insufficient evidence; not routinely recommended [19]

Ineffective Treatments

• Antibiotics: No benefit for viral rhinosinusitis [3]
• Oral corticosteroids: Limited evidence; not routinely recommended [19]
• Zinc: Conflicting evidence
• Vitamin C: No proven benefit for treatment
• Echinacea: No proven benefit

Acute Bacterial Rhinosinusitis (Antibiotic Therapy)

Indications for Antibiotic Therapy

Antibiotics are indicated when patient meets one or more IDSA/AAO-HNS criteria: [1,19]

1. Persistent symptoms ≥10 days without improvement
2. Severe symptoms at onset (≥3 days): Fever ≥39°C + purulent discharge + facial pain
3. Worsening symptoms after initial improvement ("double-sickening")

First-Line Antibiotic Therapy

Amoxicillin-clavulanate is the first-line agent due to: [1,16]

• Coverage of S. pneumoniae (including penicillin-resistant strains at high dose)
• β-lactamase inhibition for H. influenzae and M. catarrhalis
• Superior efficacy compared to amoxicillin alone
• Favorable safety profile

Recent evidence on high-dose vs. standard-dose: A 2021 randomized trial found no significant difference in clinical cure rates between high-dose and standard-dose amoxicillin-clavulanate for adults with acute sinusitis, but high-dose was associated with more diarrhea. [24] Standard dose is appropriate for most patients unless high local resistance or recent antibiotic exposure.

Duration: 5-7 days is as effective as 10-14 days with reduced adverse effects and less resistance selection. [25]

Second-Line and Alternative Regimens

For penicillin allergy (non-severe):

For severe penicillin allergy (anaphylaxis):

• Levofloxacin or moxifloxacin (avoid cephalosporins due to cross-reactivity)

NOT recommended as first-line (high resistance rates): [1]

• Amoxicillin alone: 30-50% H. influenzae and > 90% M. catarrhalis are resistant
• Trimethoprim-sulfamethoxazole: 30-40% S. pneumoniae resistance
• Macrolides (azithromycin, clarithromycin): 30-40% S. pneumoniae resistance, high H. influenzae resistance

Treatment Failure

Definition: No improvement after 3-5 days or worsening at any time during therapy.

Management approach:

1. Reassess diagnosis: Consider alternative diagnoses (see Differential Diagnosis)
2. Assess compliance: Confirm patient taking medication as prescribed
3. Consider complications: Examine for orbital/intracranial signs; image if concerned
4. Consider resistant organisms: Switch to broader-spectrum antibiotic or fluoroquinolone
5. Consider odontogenic source: Dental examination; odontogenic sinusitis may require dental intervention
6. Refer to ENT: For consideration of:
   • Nasal endoscopy
   • Sinus aspiration for culture (rarely needed)
   • Imaging if not yet done
   • Functional endoscopic sinus surgery (FESS) if structural abnormality or chronic disease

Antibiotic options for treatment failure:

• If initial therapy was amoxicillin-clavulanate: Switch to levofloxacin or moxifloxacin
• If initial therapy was doxycycline: Switch to amoxicillin-clavulanate (high-dose) or fluoroquinolone
• Consider broadening coverage for resistant organisms or anaerobes

Adjunctive Therapies

Complicated Acute Rhinosinusitis

Orbital Complications

Preseptal cellulitis (Chandler Stage I):

• Antibiotics: IV antibiotics initially, transition to oral when improving
  • "Regimen: Ampicillin-sulbactam 1.5-3g IV q6h OR ceftriaxone 1-2g IV q24h + metronidazole 500mg IV q8h"
• Monitoring: Ophthalmology examination every 12-24 hours for progression
• Duration: 48-72 hours IV, then oral step-down to complete 10-14 days total
• Imaging: CT orbits/sinuses to confirm diagnosis and exclude deeper involvement

Orbital cellulitis / Subperiosteal abscess (Chandler Stage II-III):

• Antibiotics: Broad-spectrum IV antibiotics
  • "Regimen: Vancomycin 15-20mg/kg IV q8-12h + ceftriaxone 2g IV q12h + metronidazole 500mg IV q8h"
  • Covers S. aureus (including MRSA), S. pneumoniae, H. influenzae, anaerobes
• Surgery: Endoscopic sinus surgery + drainage if:
  • Abscess > 10mm or medial to medial rectus
  • No improvement after 24-48 hours IV antibiotics
  • Worsening vision or ophthalmoplegia
• Monitoring: Serial ophthalmology assessments (visual acuity, extraocular movements, pupillary responses)

Orbital abscess (Chandler Stage IV):

• Emergency surgical drainage + IV antibiotics
• High risk of vision loss; urgent ENT and ophthalmology consultation

Intracranial Complications

• Antibiotics: High-dose IV antibiotics with CNS penetration
  • "Regimen: Vancomycin 15-20mg/kg IV q8-12h + ceftriaxone 2g IV q12h + metronidazole 500mg IV q8h"
  • "Duration: Minimum 4-6 weeks IV (longer for brain abscess)"
• Imaging: MRI brain with contrast (superior to CT for abscess/empyema characterization)
• Neurosurgical consultation: Emergency for:
  • Subdural empyema
  • Brain abscess
  • Epidural abscess with mass effect
• Surgical intervention: Craniotomy for drainage of empyema/abscess + endoscopic sinus surgery to address source
• Anticoagulation: Controversial for cavernous sinus thrombosis; consult hematology

Invasive Fungal Sinusitis (Immunocompromised)

• Medical emergency with high mortality (30-70%)
• Risk factors: Neutropenia, hematopoietic stem cell transplant, diabetes with ketoacidosis, solid organ transplant, chronic corticosteroid use
• Clinical features: Rapidly progressive, black nasal discharge/eschar, facial swelling, cranial nerve palsies, palatal perforation
• Diagnosis: Urgent biopsy showing tissue invasion by fungal hyphae
• Treatment:
  • "Antifungal therapy: Liposomal amphotericin B 5-10mg/kg/day IV (first-line)"
  • "Emergency surgical debridement: Extensive resection of necrotic tissue"
  • "Reverse immunosuppression: Discontinue corticosteroids, stimulate neutrophil recovery (G-CSF)"
  • "Correct metabolic derangement: Aggressive glucose control if diabetic ketoacidosis"
• Prognosis: Mortality 30-70%; survival depends on early diagnosis, aggressive surgery, and immune reconstitution

---

Special Populations

Pregnancy

Physiological changes: Pregnancy increases risk of rhinosinusitis due to:

• Estrogen-induced nasal mucosal hyperemia and edema
• Increased blood volume and vascular engorgement
• Impaired mucociliary clearance

Management principles:

• Saline irrigation: Safe and effective; first-line treatment
• Intranasal corticosteroids: Generally safe (Category B/C depending on agent); budesonide is preferred (Category B)
• Oral decongestants: Avoid in first trimester (association with gastroschisis); pseudoephedrine may reduce placental perfusion
• Topical decongestants: Limit to ≤3 days if necessary
• Analgesics: Paracetamol is safe; avoid NSAIDs in third trimester (risk of premature closure of ductus arteriosus)
• Antibiotics: Amoxicillin-clavulanate is safe (Category B); avoid fluoroquinolones and doxycycline

Immunocompromised Patients

Increased risk of:

• Progression to bacterial infection
• Invasive fungal sinusitis
• Complications (orbital, intracranial)
• Atypical organisms

Management approach:

• Lower threshold for imaging: CT sinuses early in course
• Broader antibiotic coverage: Consider early use of fluoroquinolones or vancomycin + ceftriaxone
• Consider fungal infection: If neutropenic, diabetes with ketoacidosis, transplant recipient, chronic steroids
• Nasal endoscopy and biopsy: If any concern for invasive fungal disease
• Earlier specialist referral: ENT consultation for persistent symptoms

HIV/AIDS patients:

• Increased frequency of bacterial sinusitis
• Higher rates of Pseudomonas aeruginosa and S. aureus
• Consider Cryptococcus, Histoplasma in endemic areas
• Correlation with low CD4 count (less than 200 cells/μL)

Elderly Patients

Considerations:

• Comorbidities (heart failure, renal impairment) affect medication selection
• Polypharmacy and drug interactions
• Atypical presentations (may lack fever)
• Increased risk of adverse effects from decongestants (hypertension, urinary retention)
• Higher risk of C. difficile infection with antibiotics

Management:

• Avoid oral decongestants if uncontrolled hypertension or cardiac disease
• Dose-adjust antibiotics for renal function
• Monitor for drug interactions
• Emphasize non-pharmacologic measures (saline irrigation)

Nosocomial Sinusitis (ICU Patients)

Risk factors:

• Nasogastric tube placement (most important)
• Nasotracheal intubation
• Nasal packing
• Supine positioning
• Impaired consciousness

Microbiology: Nosocomial organisms

• Pseudomonas aeruginosa
• Staphylococcus aureus (MRSA)
• Acinetobacter species
• Gram-negative bacilli

Diagnosis:

• High index of suspicion in ventilated patients with fever of unknown source
• CT sinuses
• Consider sinus aspiration for culture

Treatment:

• Remove nasogastric/nasotracheal tubes if possible
• Broad-spectrum antibiotics covering nosocomial pathogens
• ENT consultation for drainage if abscess or no improvement

---

Prognosis

Natural History

Viral rhinosinusitis:

• Spontaneous resolution: 70-80% resolve within 7-10 days without antibiotics [3,4]
• Symptom trajectory: Peak severity days 2-4, gradual improvement by day 7-10
• Post-viral cough/congestion: May persist 2-4 weeks due to ciliary dysfunction and residual inflammation

Acute bacterial rhinosinusitis:

• With antibiotic therapy: 85-90% clinical cure by 10-14 days [1]
• Without antibiotics: 60-70% spontaneous resolution (NNT for antibiotics ~15-18) [3]
• Time to symptom resolution: Median 7-10 days with antibiotics vs. 10-14 days without
• Symptom improvement: Typically within 3-5 days of starting appropriate antibiotics

Outcomes with Treatment

Prognostic Factors

Favorable prognosis:

• First episode
• No comorbidities
• Immunocompetent
• Appropriate antibiotic therapy
• Compliance with treatment

Poor prognostic factors:

• Immunocompromised state
• Recurrent episodes
• Anatomical abnormalities
• Odontogenic source (requires dental treatment)
• Nosocomial infection
• Resistant organisms
• Biofilm formation [18]

Long-Term Outcomes

Progression to chronic rhinosinusitis:

• 5-10% of patients with recurrent acute rhinosinusitis develop chronic disease (symptoms > 12 weeks)
• Risk factors: Anatomical abnormalities, nasal polyps, allergic rhinitis, aspirin-exacerbated respiratory disease, cystic fibrosis, primary ciliary dyskinesia, immunodeficiency

Recurrent acute rhinosinusitis:

• Defined as ≥4 episodes/year, each less than 4 weeks duration, with complete resolution between episodes
• Warrants ENT referral for anatomical evaluation (CT sinuses) and consideration of functional endoscopic sinus surgery (FESS) if structural abnormality identified

---

Prevention

Primary Prevention

Infection prevention:

• Hand hygiene to reduce viral transmission
• Avoid close contact with individuals with upper respiratory infections
• Annual influenza vaccination (reduces influenza-associated sinusitis)
• Pneumococcal vaccination (for at-risk populations)

Environmental measures:

• Smoking cessation (active smoking increases risk 2-fold)
• Avoid secondhand smoke exposure
• Air filtration/humidification in dry climates
• Avoid prolonged exposure to air pollution and irritants

Management of predisposing conditions:

• Allergic rhinitis: Intranasal corticosteroids, allergen avoidance, immunotherapy
• Anatomical abnormalities: Surgical correction if symptomatic (septoplasty, turbinate reduction)
• Gastroesophageal reflux: Proton pump inhibitors if GERD contributes to rhinosinusitis
• Dental hygiene: Regular dental care to prevent odontogenic infection

Secondary Prevention (Preventing Recurrence)

For patients with recurrent acute rhinosinusitis:

• Saline nasal irrigation: Daily prophylactic use reduces recurrence [21]
• Intranasal corticosteroids: Continuous use if allergic component
• Identify and manage underlying causes:
  • Allergy testing and management
  • Immunodeficiency evaluation if severe/recurrent infections
  • CT sinuses to identify anatomical abnormalities
• Avoid overuse of antibiotics: May disrupt normal flora and predispose to recurrence
• Functional endoscopic sinus surgery (FESS): For anatomical correction in refractory cases

Antibiotic Stewardship

Reducing unnecessary antibiotic use: [6]

• Educate patients on viral vs. bacterial distinction
• Emphasize that most cases are viral and self-limited
• Provide symptomatic treatment and reassurance
• Use delayed antibiotic prescription strategy (fill if not improving in 7 days)
• Avoid prescribing antibiotics for viral URI to prevent sinusitis (ineffective)

---

Key Guidelines

International Guideline Recommendations

1. IDSA Clinical Practice Guideline (2012) [1]

   • Defines criteria for acute bacterial rhinosinusitis diagnosis
   • Amoxicillin-clavulanate as first-line antibiotic
   • 5-7 day antibiotic duration
   • Imaging not recommended for uncomplicated cases

2. AAO-HNS Clinical Practice Guideline (2015, Updated 2025) [19]

   • Clinical diagnosis based on symptoms
   • Distinguishes viral from bacterial infection
   • Recommends saline irrigation and intranasal corticosteroids
   • Restricts antibiotic use to bacterial criteria

3. EPOS 2020 (European Position Paper on Rhinosinusitis and Nasal Polyps) [19]

   • Comprehensive evidence-based recommendations
   • Symptom-based diagnostic criteria
   • Stepwise treatment approach
   • Emphasis on patient-reported outcome measures

4. Cochrane Systematic Reviews

   • Antibiotics for acute rhinosinusitis (2018): NNT 15-18 for symptom improvement; recommend restricting to bacterial criteria [3]
   • Saline irrigation (2019): Effective for symptom relief in acute and chronic rhinosinusitis [21]

---

Exam-Focused Content

Common MRCP/PLAB/USMLE Questions

1. "A 35-year-old presents with 12 days of nasal congestion, purulent discharge, and facial pain without improvement. What is the most appropriate management?"

   • Answer: Amoxicillin-clavulanate 875/125mg BID for 5-7 days (meets persistent symptom criterion for ABRS)

2. "What clinical feature best distinguishes bacterial from viral rhinosinusitis?"

   • Answer: Symptoms persisting ≥10 days without improvement OR biphasic illness with worsening after initial improvement

3. "A patient with acute sinusitis develops periorbital swelling and proptosis. What is the most appropriate next step?"

   • Answer: Urgent CT orbits/sinuses with IV contrast + ophthalmology consultation + IV antibiotics

4. "What is the most common bacterial pathogen in acute bacterial rhinosinusitis?"

   • Answer: Streptococcus pneumoniae (30-40%)

5. "Which antibiotic is NOT recommended as first-line for acute bacterial rhinosinusitis due to high resistance?"

   • Answer: Azithromycin (macrolide resistance 30-40%)

Viva Points

Viva Point: Opening statement: "Acute rhinosinusitis is symptomatic inflammation of the nasal cavity and paranasal sinuses lasting less than 4 weeks. The vast majority—90-98%—is viral and self-limiting, resolving within 7-10 days. Acute bacterial rhinosinusitis develops in only 0.5-2% of viral upper respiratory infections and requires specific clinical criteria for diagnosis to guide appropriate antibiotic therapy."

Key facts to mention:

• Epidemiology: 31 million cases annually in the US; leading cause of antibiotic overprescription [2,6]
• Diagnosis: Clinical diagnosis based on ≥2 symptoms (nasal obstruction/discharge PLUS facial pain or hyposmia) for less than 4 weeks [19]
• Bacterial criteria (IDSA): (1) Symptoms ≥10 days without improvement, OR (2) Severe onset (fever ≥39°C + purulent discharge + facial pain ≥3 days), OR (3) "Double-sickening" [1]
• First-line treatment: Amoxicillin-clavulanate 875/125mg BID for 5-7 days for bacterial infection [1,16]
• Complications: Orbital (most common, 0.5-2%) and intracranial (less than 1%) require urgent imaging and IV antibiotics [8,9]

Classification to mention:

• By duration: Acute (less than 4 weeks), subacute (4-12 weeks), chronic (> 12 weeks)
• By etiology: Viral (90-98%), bacterial (0.5-2%), fungal (rare)

Common pitfalls:

• Purulent discharge does NOT distinguish viral from bacterial (neutrophil recruitment occurs in both)
• Imaging is NOT indicated for uncomplicated cases
• Amoxicillin alone is NOT first-line (β-lactamase-producing organisms)

Common Mistakes

❌ Prescribing antibiotics for viral rhinosinusitis

• Most cases (90-98%) are viral and self-limiting
• Antibiotics do not shorten viral illness duration
• Contribute to resistance and adverse effects

❌ Using purulent discharge color as sole criterion for bacterial infection

• Yellow/green discharge occurs in both viral and bacterial infection
• Use IDSA criteria (duration ≥10 days, severe onset, or biphasic course)

❌ Ordering CT sinuses for uncomplicated acute rhinosinusitis

• Imaging not needed for clinical diagnosis
• Reserve for complications, recurrent disease, or failed therapy

❌ Prescribing macrolides (azithromycin) as first-line

• High resistance rates (30-40%) in S. pneumoniae
• Amoxicillin-clavulanate is evidence-based first-line [1]

❌ Missing orbital complications

• Any periorbital swelling, proptosis, or vision changes require urgent ophthalmology consultation and imaging
• Orbital cellulitis can rapidly progress to vision loss

❌ Prolonged topical decongestant use

• Limit to ≤3 days to avoid rhinitis medicamentosa (rebound congestion)

❌ Failing to educate patients on viral vs. bacterial distinction

• Patient education reduces antibiotic-seeking behavior
• Explain that most cases resolve without antibiotics

Model Answers

Q: "A 42-year-old woman presents with 8 days of nasal congestion, facial pressure, and purulent nasal discharge. She has no fever. On examination, there is purulent rhinorrhea and maxillary sinus tenderness. Describe your management."

A: "This patient has acute rhinosinusitis, most likely viral given the 8-day duration without reaching the 10-day threshold for bacterial infection. I would not prescribe antibiotics at this stage. My management would focus on symptomatic relief:

First, I would recommend saline nasal irrigation 2-3 times daily, which has Level I evidence for symptom improvement. I would prescribe intranasal corticosteroids such as mometasone furoate, which provide modest symptom relief. For facial pain, I would recommend paracetamol or ibuprofen as needed.

I would provide patient education explaining that most rhinosinusitis is viral and self-limiting, typically resolving within 7-10 days. I would advise her to return if symptoms persist beyond 10 days without improvement, worsen at any point, or if she develops warning signs of complications such as periorbital swelling, vision changes, severe headache, or altered mental status.

If she returns at day 12-14 with persistent symptoms, I would then diagnose acute bacterial rhinosinusitis and initiate amoxicillin-clavulanate 875/125mg twice daily for 5-7 days, as this is the first-line antibiotic per IDSA guidelines."

---

Q: "What are the indications for imaging in acute rhinosinusitis?"

A: "Imaging, specifically CT sinuses with IV contrast if complications are suspected, is indicated in the following scenarios:

1. Suspected complications: Any orbital signs (periorbital swelling, proptosis, ophthalmoplegia, vision changes) or intracranial signs (severe headache, altered mental status, focal neurological deficits, meningismus) require urgent CT to identify orbital cellulitis, abscess, meningitis, or intracranial extension.

2. Recurrent acute rhinosinusitis: Defined as four or more episodes per year to evaluate for underlying anatomical abnormalities such as septal deviation, concha bullosa, or chronic mucosal disease that may benefit from surgical correction.

3. Failed medical therapy: Symptoms persisting after two appropriate courses of antibiotics to exclude alternative diagnoses such as fungal infection, neoplasm, or odontogenic sinusitis.

4. Immunocompromised patients: Lower threshold for imaging given higher risk of invasive fungal sinusitis and complications.

5. Pre-operative planning: If functional endoscopic sinus surgery is being considered.

Importantly, imaging is NOT indicated for uncomplicated acute rhinosinusitis, as it is a clinical diagnosis and routine imaging leads to overdiagnosis, unnecessary cost, and radiation exposure."

---

References

1. Chow AW, Benninger MS, Brook I, et al. IDSA clinical practice guideline for acute bacterial rhinosinusitis in children and adults. Clin Infect Dis. 2012;54(8):e72-e112. doi:10.1093/cid/cir1043

2. Rosenfeld RM, Piccirillo JF, Chandrasekhar SS, et al. Clinical practice guideline (update): adult sinusitis. Otolaryngol Head Neck Surg. 2015;152(2 Suppl):S1-S39. doi:10.1177/0194599815572097

3. Lemiengre MB, van Driel ML, Merenstein D, et al. Antibiotics for acute rhinosinusitis in adults. Cochrane Database Syst Rev. 2018;9(9):CD006089. doi:10.1002/14651858.CD006089.pub5

4. Aring AM, Chan MM. Acute rhinosinusitis in adults. Am Fam Physician. 2016;94(2):97-105. PMID:27386721

5. DeMuri GP, Wald ER. Acute bacterial sinusitis in children. N Engl J Med. 2012;367(12):1128-1134. doi:10.1056/NEJMcp1106638

6. Shapiro DJ, Gonzales R, Cabana MD, Hersh AL. National trends in visit rates and antibiotic prescribing for adults with acute sinusitis. JAMA Intern Med. 2011;171(20):1818-1820. doi:10.1001/archinternmed.2011.277

7. Gwaltney JM Jr. Acute community-acquired sinusitis. Clin Infect Dis. 1996;23(6):1209-1223. doi:10.1093/clinids/23.6.1209

8. Chandler JR, Langenbrunner DJ, Stevens ER. The pathogenesis of orbital complications in acute sinusitis. Laryngoscope. 1970;80(9):1414-1428. doi:10.1288/00005537-197009000-00007

9. Gallagher RM, Gross CW, Phillips CD. Suppurative intracranial complications of sinusitis. Laryngoscope. 1998;108(11):1635-1642. doi:10.1097/00005537-199811000-00009

10. Hastan D, Fokkens WJ, Bachert C, et al. Chronic rhinosinusitis in Europe—an underestimated disease. A GA²LEN study. Allergy. 2011;66(9):1216-1223. doi:10.1111/j.1398-9995.2011.02646.x

11. Meltzer EO, Hamilos DL. Rhinosinusitis diagnosis and management for the clinician: a synopsis of recent consensus guidelines. Mayo Clin Proc. 2011;86(5):427-443. doi:10.4065/mcp.2010.0392

12. Akdis CA, Bachert C, Cingi C, et al. Endotypes and phenotypes of chronic rhinosinusitis: a PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma & Immunology. J Allergy Clin Immunol. 2013;131(6):1479-1490. doi:10.1016/j.jaci.2013.02.036

13. Gliklich RE, Metson R. The health impact of chronic sinusitis in patients seeking otolaryngologic care. Otolaryngol Head Neck Surg. 1995;113(1):104-109. doi:10.1016/S0194-5998(95)70152-4

14. Brook I. Microbiology of acute and chronic sinusitis in children and adults. Ann Otol Rhinol Laryngol. 2016;125(5):428-434. doi:10.1177/0003489415607194

15. Jenkins SG, Farrell DJ. Increase in pneumococcus macrolide resistance, United States. Emerg Infect Dis. 2009;15(8):1260-1264. doi:10.3201/eid1508.081187

16. Gregory J, Patel N, Aronson PL, et al. High-dose vs standard-dose amoxicillin plus clavulanate for adults with acute sinusitis: a randomized clinical trial. JAMA Netw Open. 2021;4(3):e211840. doi:10.1001/jamanetworkopen.2021.1840

17. Hwang PH. Acute invasive fungal rhinosinusitis. UpToDate. Accessed January 9, 2026.

18. Hall-Stoodley L, Hu FZ, Gieseke A, et al. Direct detection of bacterial biofilms on the middle-ear mucosa of children with chronic otitis media. JAMA. 2006;296(2):202-211. doi:10.1001/jama.296.2.202

19. Fokkens WJ, Lund VJ, Hopkins C, et al. European Position Paper on Rhinosinusitis and Nasal Polyps 2020. Rhinology. 2020;58(Suppl S29):1-464. doi:10.4193/Rhin20.600

20. Young J, De Sutter A, Merenstein D, et al. Antibiotics for adults with clinically diagnosed acute rhinosinusitis: a meta-analysis of individual patient data. Lancet. 2008;371(9616):908-914. doi:10.1016/S0140-6736(08)60416-2

21. King D, Mitchell B, Williams CP, Spurling GK. Saline nasal irrigation for acute upper respiratory tract infections. Cochrane Database Syst Rev. 2015;(4):CD006821. doi:10.1002/14651858.CD006821.pub3

22. Zalmanovici Trestioreanu A, Yaphe J. Intranasal steroids for acute sinusitis. Cochrane Database Syst Rev. 2013;(12):CD005149. doi:10.1002/14651858.CD005149.pub4

23. Eccles R, Jawad MS, Jawad SS, Angello JT, Druce HM. Efficacy and safety of single and multiple doses of pseudoephedrine in the treatment of nasal congestion associated with common cold. Am J Rhinol. 2005;19(1):25-31. PMID:15794071

24. Gregory J, Patel N, Aronson PL, et al. High-dose vs standard-dose amoxicillin plus clavulanate for adults with acute sinusitis: a randomized clinical trial. JAMA Netw Open. 2021;4(3):e211840. doi:10.1001/jamanetworkopen.2021.1840

25. Falagas ME, Giannopoulou KP, Vardakas KZ, et al. Comparison of antibiotics with placebo for treatment of acute sinusitis: a meta-analysis of randomised controlled trials. Lancet Infect Dis. 2008;8(9):543-552. doi:10.1016/S1473-3099(08)70202-0